Search
-
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates
(PLoS ONE. vol. 13, n° 11, pp. e0207794, 2018-11-30)Article de revueOpen access -
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study
(The Lancet Infectious Diseases. vol. 20, n° 5, pp. 585-597, 2020)Article de revue -
Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect
(Journal of Immunological Methods. vol. 477, pp. 112711, 2020)Article de revue -
Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1–Infected Patients
(Journal of Acquired Immune Deficiency Syndromes. vol. Publish Ahead of Print, 2020-12-17)Article de revue -
T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B
(AIDS Research and Human Retroviruses. pp. 16-16, 2018-10)Article de revue -
A Phase Ia/B Study To Assess The Safety And Immunogenicity Of Placental Malaria Vaccine Candidate: Preliminary Results Of The Primalvac Trial
(American Journal of Tropical Medicine and Hygiene. vol. 99, n° 4, pp. 469-469, 2018)Article de revue -
Durable natural killer cell responses after heterologous two-dose Ebola vaccination
(NPJ vaccines. vol. 6, n° 1, pp. 19, 2021-01-29)Article de revueOpen access -
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
(PLoS Medicine. vol. 19, n° 1, 2022-01-11)Article de revueOpen access -
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)
(Trials. vol. 21, n° 1, pp. 846, 2020-10-13)Article de revueOpen access -
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
(The Lancet Infectious Diseases, 2020-11-17)Article de revue